Immunogenicity of small‐cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition
Open Access
- 11 August 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 4864-4881
Abstract
Introduction: The activation of STING (stimulator of interferon genes) pathway enhances antitumor immunity in small‐cell lung cancer (SCLC), while the DNA damage induced by non‐cGAMP‐based agonists is a potent inducer of STING activity. Here, we investigate the intrinsic expression of STING in cancer cells and evaluate the value of the combination of ATR and TOP1 inhibitors in enhancing antitumor immunity.Methods: STING expression was assessed at mRNA and protein levels in SCLC and normal lung tissues. Transcriptomic subsets of SCLC were identified based on STING‐related genes. Distinct mutation and immunogenomic profiles of these subsets were determined. The direct antitumor efficacy and the potential of enhancing antitumor immunity of the strategy using the ATR‐TOP1‐inhibitor combination were tested in SCLC cell lines.Results: The intrinsic expression of STING was significantly reduced in SCLC compared to normal lung tissues (p < 0.0001). Three STING‐related SCLC subtypes were identified in which the STING‐high subtype was associated with (1) high immune infiltration, (2) high expression of genes related to MHC and immune checkpoints, and (3) high EMT and ferroptosis score. On the contrary, the STING‐low subtype was enriched with pathways related to DNA damage response (DDR) and cell cycle progression. The association between the DDR pathway activity and the STING‐IFN innate immune response was verified by in vitro experiments in which the inhibition of ATR and TOP1 triggered the expression of genes encoding type I IFN signaling and pro‐inflammatory cytokines/chemokines in a STING‐low SCLC cell line.Conclusion: Our study verifies that activation of the STING‐IFN response by ATR and TOP1 inhibitors might be a therapeutic strategy to improve the response to immune checkpoint therapy in STING‐low SCLC. Furthermore, the combinations of ATR and TOP1 inhibitors can augment tumor inflammation in STING‐low SCLC.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (X2YXD2172070)
- Natural Science Foundation of Guangdong Province (2021A1515012123)
This publication has 47 references indexed in Scilit:
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and SignalingMolecular Cell, 2014
- Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics, 2014
- PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancerScientific Reports, 2013
- Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung CancersScience Translational Medicine, 2013
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Cancer Discovery, 2012
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005